Cargando…
An integrated artificial intelligence model for efficiency assessment in pharmaceutical companies during the COVID-19 pandemic
The spread of coronavirus disease around the world has had an immense impact on most economic sectors. Yet amid the turmoil and chaos from the worldwide pandemic, one industry is thriving noticeably. The coronavirus disease is a once in a lifetime business opportunity for pharmaceutical companies. T...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724018/ http://dx.doi.org/10.1016/j.susoc.2022.01.003 |
Sumario: | The spread of coronavirus disease around the world has had an immense impact on most economic sectors. Yet amid the turmoil and chaos from the worldwide pandemic, one industry is thriving noticeably. The coronavirus disease is a once in a lifetime business opportunity for pharmaceutical companies. This study presents an artificial intelligence method composed of optimization and machine learning. Data envelopment analysis (DEA) is used to measure productivities and efficiencies of pharmaceutical companies during the COVID-19 pandemic using the additive model in window analysis, the BCC (Banker-Charnes-Cooper) model, and the CCR (Charnes-Cooper-Rhodes) model. The three models are assessed using DataStream financial information with research and development (R&D) investment. The results indicated the additive model's superiority in window analysis, followed by the BCC and CCR models. In the end, some of well-known data mining algorithms, based on the suggested data, have been evaluated in various tools to find the most efficient tool and algorithm. |
---|